Pfizer shares positive five-year results for Lorbrena in advanced lung cancer

03 Jun 2024
pmlive.com
Clinical ResultASCOPhase 3
Pfizer shares positive five-year results for Lorbrena in advanced lung cancer
Preview
Source: PMLiVE
Pfizer has shared positive longer-term follow-up results from a late-stage study of its anaplastic lymphoma kinase (ALK) inhibitor Lorbrena (lorlatinib) in advanced non-small cell lung cancer (NSCLC).
The phase 3 CROWN trial has been comparing the drug to Pfizer’s tyrosine kinase inhibitor Xalkori (crizotinib) in patients with previously untreated ALK-positive disease.
Results, presented at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in the Journal of Clinical Oncology, showed that 60% of patients treated with Lorbrena were alive without disease progression after five years compared to 8% of those in the Xalkori cohort.
The updated results also demonstrated an 81% reduction in the rate of disease progression or death and a 94% reduction in the risk of developing intracranial progression in the Lorbrena treatment arm compared to the Xalkori group.
The safety profiles of both drugs in the five-year follow-up were consistent with previous findings, with no new safety signals reported for Lorbrena.
Roger Dansey, chief development officer of oncology at Pfizer, said: “These results from the CROWN trial are unprecedented… and support Lorbrena as a standard of care for the first-line treatment of people with ALK-positive advanced NSCLC.”
Lung cancer is the number one cause of cancer-related death globally and NSCLC accounts for up to 85% of all diagnoses.
ALK-positive tumours occur in 3% to 5% of NSCLC cases, translating to approximately 72,000 people who are diagnosed worldwide every year.
Lorlatinib, which already holds approvals to treat certain adults with ALK-positive NSCLC, is designed to inhibit tumour mutations that drive resistance to other ALK inhibitors and to penetrate the blood-brain barrier.
Principal investigator of CROWN, Benjamin Solomon, Peter MacCallum Cancer CentreCancer Centre, said: “This updated analysis shows that Lorbrena helped patients live longer without disease progression, with the majority of patients experiencing sustained benefit for over five years, including nearly all patients having protection from progression of disease in the brain.
“These improvements in outcomes for patients with ALK-positive NSCLC represent a remarkable advancement in lung cancer.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.